Member Info for ChrisToffer

Hi Vorag, the P3 trial is not open yet however i believe it is over 18's only. They may have some luck with the MAP but not sure.

https://www.synairgen.com/covid-19/#managedaccess

How we laughed when Acacia dumped their shares and a few days later we had a 500% rise..

DP, can you point me to where SNG 'declared that they would do a deal with big pharma in 'weeks'?

Also, of the 140 drugs in development, can you point to those that have been P2 peer reviewed with more promise than SNG001?

Thanks SS, very fair point on Acacia who must have been kicking themselves after 20th July.

Hi Ss, good to hear from ya! Have you heard any plausible reasoning for LL selling? He's been in SNG for a long time so I imagine he's still banking some profit!

I wouldnt expect P3 start to boost the SP too much. It didn't in march. Commercial announcements are what it really needs however BJ just announced a need for treatments throughout next year and SNG001 has the most promising dataset of them all. Patience!

Thanks Russky!

"Effective treatments for COVID-19 will continue to be vital to manage the virus even as vaccines are rolled out in the UK and globally, including for those who cannot be vaccinated, for example because they are immunocompromised. Finding effective
treatments will reduce risk to lives and serious illness for people who do contract the virus and support the return to normal life."

'If Moderna Pfizer and AstraZeneca all get approval then they have enough doses to vaccinate the whole of the UK.'

Even if that happened, which is a mammoth task that assumes everything goes in the UK's favour, it would still leave 10% (6.6 million people!) with a need for treatments to be in place.

Think about the scale here guys. Theres plenty of room for SNGs 100k treatments a month.

It is difficult for anyone with a higher averages to weather these storms. Holders from pre 20th July went through the exact same over the course of a few months, when the risk was arguably higher.

However anyone that thinks prevention (through vaccination) is going to overcome the need for treatments anytime soon is not seeing the scale of the problem.

All the best to you and our parents CW!

winwinwine filtered
Robsaunders filtered

Pair of oxygen thieves!

Completely agree Miggy! RM listed a few separate revenue streams the other night and any one of them is worth a lot more than the current mcap.

"Anyways I've had enough of myself now"

I highly doubt that....

You talk some 5h1te whiney

Also worth bearing in mind that £2 previously equated to roughly 300m MCAP . With the dilution a 300M MCAP is now £1.50 a share.

Must have borrowed Septic Peg's ball

The trial has a DMC which can monitor progress of the trial and recommend early unblinding in the event of good efficacy.

https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-data-monitoring-committees_en.pdf

bdcarr, it is 100,00k treatments a month, not doses. You would divide by 14 if it were doses and that would be them aiming to treat 7000 patients a month - which would be a huge underestimation of the need.

According to the 2nd November RNS the shares would be issued on the 4th, conditional only on Admission becoming effective. In my mind this supersedes the 18th november date mentioned in 14th Oct RNS. So either we have lots of II's below the threshold or someone is bending the rules.....

Do we really think that the £80m was raised through different investors whilst none of them broke the 3 or 5% thresholds? It was something that got overlooked last night. I've emailed consilium to ask the question but not sure it's their responsibility to inform the market.